Drug Trial Radar · NCT07134907
The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH
Last checked: Nov 20, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Jul 18, 2022
Primary completion
Jul 9, 2024
Study completion Jul 9, 2024
Sponsor
- Lead sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 60 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if Qianweitai (QWT, silodosin capsule) works to treat BPH/LUTS in male adults. It will also learn the safety about QWT. The main questions it aims to answer are: 1. Whether QWT is non inferior to tamsulosin in the reduction of IPSS total score? 2. Dose QWT have other advantages in the improvement of LUTS? Participants will: 1. Orally take QWT twice daily or tamsulosin once daily for 12 weeks. 2. Visit the clinic at week 1、 2、4、8 and 12 for checkups and tests.
Conditions
- BPH (Benign Prostatic Hyperplasia)
Interventions
SilodosinDrug
Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.
TamsolusinDrug
Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- International Prostate Symptom Score(IPSS)Time frame: week 12
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Ciivil Aviation General Hospital
Beijing, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Wuhan Center Hospital
Wuhan, Hubei, China
Wuhan No.1 Hospital
Wuhan, Hubei, China
The Second Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.